Pharmaceutical - Lundbeck

Filter

Current filters:

Lundbeck

Popular Filters

1 to 25 of 99 results

Link between immune system and brain diseases to be researched by Lundbeck

22-12-2014

Danish CNS specialist drugmaker Lundbeck is involved in new groundbreaking research that will investigate…

ImmunologicalsJanssenLundbeckNeurologicalPharmaceuticalResearch

Lundbeck to stop further development of desmoteplase

Lundbeck to stop further development of desmoteplase

18-12-2014

Following evaluation of disappointing clinical results, Danish CNS specialists Lundbeck said late yesterday…

Cardio-vasculardesmoteplaseFinancialLundbeckNeurologicalPharmaceuticalResearch

Lundbeck and Otsuka present Phase III results of brexpiprazole in major depressive disorder

Lundbeck and Otsuka present Phase III results of brexpiprazole in major depressive disorder

10-12-2014

Japanese drug maker Otsuka and Danish CNS specialist Lundbeck have announced Phase III study results…

brexpiprazoleLundbeckNeurologicalOtsukaPharmaceuticalResearchUSA

Labeling update of Lundbeck and Otsuka’s Abilify Maintena approved by FDA

08-12-2014

The US Food and Drug Administration approved the labeling update of Abilify Maintena (aripiprazole) for…

Abilify MaintenaLundbeckNeurologicalOtsuka PharmaceuticalPharmaceuticalRegulationUSA

Added benefit of Lundbeck’s Selincro not proven, says IQWiG

04-12-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment…

GermanyLundbeckNeurologicalPharmaceuticalPricingRegulationSelincro

The Global Crisis of Depression conference: high co-morbidity, high costs, few answers

The Global Crisis of Depression conference: high co-morbidity, high costs, few answers

27-11-2014

John Andrews, consultant editor of The Economist, opened the Global Crisis of Depression conference by…

InterviewsLundbeckNeurologicalPharmaceuticalResearchSocial IssuesUK

UK's NICE recommends Selincro to help reduce alcohol dependence

UK's NICE recommends Selincro to help reduce alcohol dependence

26-11-2014

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Selincro (nalmefene)…

LundbeckNeurologicalPharmaceuticalRegulationSelincroUK

New products do well, but sales and profit down at Lundbeck

New products do well, but sales and profit down at Lundbeck

05-11-2014

In what was clearly a difficult period for Danish CNS specialist Lundbeck due to patient expiries, the…

EuropeFinancialLundbeckNeurologicalPharmaceutical

Abilify Maintena shows superior efficacy to paliperidone palmitate

Abilify Maintena shows superior efficacy to paliperidone palmitate

04-11-2014

Danish CNS specialist Lundbeck and the US subsidiary of Japan’s Otsuka Pharmaceutical have released…

Abilify MaintenaLundbeckNeurologicalOtsuka Pharmaceuticalpaliperidone palmitatePharmaceuticalResearch

FDA requests CMC data on Lundbeck’s Carbella application

25-10-2014

Danish CNS drug specialist Lundbeck says that it has received a Complete Response Letter (CRL) from the…

CarbamazepineCarbellaLigand PharmaceuticalsLundbeckNeurologicalPharmaceuticalRegulationUSA

NICE recommends Lundbeck’s Selincro for alcohol dependence

NICE recommends Lundbeck’s Selincro for alcohol dependence

02-10-2014

Today’s announcement that the UK’s National Institute for Health and Care Excellence (NICE) recommends…

Biotie TherapiesLundbeckNeurologicalPharmaceuticalPricingRegulationSelincroUK

FDA accepts NDA filing for Lundbeck and Otsuka's brexpiprazole

FDA accepts NDA filing for Lundbeck and Otsuka's brexpiprazole

24-09-2014

The US Food and Drug Administration has accepted the filing for review of brexiprazole for the treatment…

CNS DiseasesLundbeckOtsukaPharmaceuticalRegulationUSA

EyeForPharma Multichannel Marketing Summit 2014: Lundbeck's Tim White on customer interaction, apps and buzzwords

EyeForPharma Multichannel Marketing Summit 2014: Lundbeck's Tim White on customer interaction, apps and buzzwords

19-09-2014

Tim White is head of global customer interaction at Lundbeck. The Pharma Letter spoke to him at the EyeForPharma…

DenmarkInterviewsLundbeckMarkets & MarketingNeurologicalPharmaceutical

Lundbeck launches Brintellix in Denmark

Lundbeck launches Brintellix in Denmark

16-09-2014

Danish CNS drug specialist Lundbeck is debutting its new antidepressant Brintellix (vortioxetine) in…

BrintellixCNS DiseasesDenmarkLundbeckMarkets & MarketingPharmaceutical

Lundbeck launches Northera in USA

Lundbeck launches Northera in USA

02-09-2014

Danish CNS specialist Lundbeck said today that Northera (droxidopa) capsules for oral use are now available…

Chelsea TherapeuticsLundbeckMarkets & MarketingNeurologicalNortheraPharmaceuticalUSA

Lundbeck and Otsuka file for US approval of brexpiprazole

Lundbeck and Otsuka file for US approval of brexpiprazole

14-07-2014

Danish CNS drug specialist Lundbeck and Japanese drugmaker Otsuka have submitted a New Drug Application…

brexpiprazoleLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceuticalPiperidinesRegulationUSA

UK’s NICE backs Lundbeck drug for alcohol dependence

UK’s NICE backs Lundbeck drug for alcohol dependence

10-07-2014

In new draft guidance, the UK drug watchdog the National Institute for Health and Care Excellence (NICE)…

LundbeckNeurologicalPharmaceuticalPricingRegulationSelincroUK

Lundbeck's desmoteplase misses primary endpoint in Ph III stroke study

28-06-2014

Danish CNS specialist Lundbeck (LUND: CO) released disappointing initial headline conclusions from DIAS-3,…

desmoteplaseLundbeckNeurologicalPharmaceutical

US psychiatrists’ views on prescribing Otsuka/Lundbeck’s brexpiprazole

26-06-2014

Surveyed US psychiatrists are receptive to novel adjunctive therapies to antidepressants for treatment-resistant…

brexpiprazoleBrintellixLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceuticalUSA

Brintellix meets primary efficacy end-point in depression study

Brintellix meets primary efficacy end-point in depression study

26-06-2014

Danish CNS drug specialist Lundbeck has announced results of the SOLUTION trial conducted in Asian patients…

BrintellixDenmarkLundbeckNeurologicalPharmaceuticalResearch

Lundbeck to complete Chelsea Thera acquisition today

Lundbeck to complete Chelsea Thera acquisition today

23-06-2014

Danish CNS specialist Lundbeck says that it has completed the tender offer to buy all of the outstanding…

Chelsea TherapeuticsLundbeckMergers & AcquisitionsNeurologicalNortheraPharmaceutical

Brintellix superior to escitalopram in improving sexual functioning for MDD patients

Brintellix superior to escitalopram in improving sexual functioning for MDD patients

17-06-2014

Danish CSN drug specialist Lundbeck has presented results about sexual functioning from a head-to-head…

BrintellixEscitalopram OxalateLundbeckMen's HealthNeurologicalPharmaceuticalResearch

1 to 25 of 99 results

COMPANY SPOTLIGHT

Menarini

Back to top